As we await the results of the VISION trial of Lu-177-PSMA-617, research continues into improving radiopharmaceuticals. … READ MORE …
Filed under: Drugs in development | Tagged: Ac-225, actinium-225, PSMA, radiopharmaceuticals, safety, side effects, targeted, xerostomia | 3 Comments »
In October 2018, the American Society of Radiation Oncologists (ASTRO) strongly endorsed moderately hypofractionated IMRT (20 or 28 treatments) for primary radiation treatment (see this link). … READ MORE …
Filed under: Uncategorized | Tagged: adverse, events, hypofractionation, safety, SBRT | 3 Comments »
We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, efficacy, Keytruda, outcome, pembrolizumab, safety, trial | 5 Comments »
In December last year we noted an announcement by Bayer that the company was unblinding data from an ongoing clinical trial because of a potential safety issue when radium-223 (Xofigo) was given in combination with abiraterone acetate + prednisone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, radium-223, safety, Xofigo, Zytiga | Leave a comment »
An interesting article has just been published in the Journal of Urology which helps to provide information (and context) about the quality of data supporting the use of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: choice, effectiveness, focused, HIFU, high-intensity, patient, preference, safety, ultrasound | 6 Comments »
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
The “Warnings and Precautions” section of the product prescribing information for enzalutamide (Xtandi) includes the following statement: … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: enzalutamide, risk, safety, seizures, Treatment | 2 Comments »
Bayer is to unblind data early from an ongoing randomized clinical trial of radium-223 acetate — on the guidance of the trial’s Independent Data Monitoring Committee (IDMC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, death, facture, radium-223, risk, safety, trial, Xofigo, Zytiga | Leave a comment »
An abstract that we missed at the ASCO meeting this year came to our attention when we read this article by Dr. Jeffrey Kirshner: “Ten practice changes I will make after attending ASCO 2017“. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, Larotrectinib, LOXO-101, safety | 5 Comments »
The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: boost, brachytherapy, effectiveness, risk, safety, Treatment, type | Leave a comment »
Is there an optimum treatment dose for sterotactic body radiation therapy (SBRT)? … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: dose, effectiveness, escalation, SABR, safety, SBRT | Leave a comment »
We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: efficacy, Lu-177, mCRPC, PSMA, safety, Treatment, trial | 2 Comments »
There have been several hypofractionation trials maturing in the last couple of years. With minor exceptions, they all tell the same story: external beam radiation therapy (EBRT) can be completed in less time without loss of efficacy or increase in toxicity. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: effectiveness, hypofractionation, radiotherapy, safety | 8 Comments »
In a newly published article on the STAT web site, two clinicians at Oregon Health and Science University argue that the benefits of immunotherapy in the treatment of cancer are being greatly over-“hyped”. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, hype, immunotherapy, safety | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 